Zobrazeno 1 - 10
of 1 194
pro vyhledávání: '"Stupp R."'
Autor:
König, D., Savic Prince, S., Hayoz, S., Zens, P., Berezowska, S., Jochum, W., Stauffer, E., Braunersreuther, V., Trachsel, B., Thierstein, S., Mark, M., Schmid, S., Curioni-Fontecedro, A., Addeo, A., Opitz, I., Guckenberger, M., Früh, M., Betticher, D.C., Ris, H.-B., Stupp, R., Rothschild, S.I., Bubendorf, L., Pless, M.
Publikováno v:
In ESMO Open August 2023 8(4)
Autor:
Alafandi, A., van Garderen, K.A., Klein, S., van der Voort, S.R., Rizopoulos, D., Nabors, L., Stupp, R., Weller, M., Gorlia, T., Tonn, J.-C., Smits, M.
Publikováno v:
In European Journal of Cancer July 2023 188:122-130
Autor:
König, D., Schär, S., Vuong, D., Guckenberger, M., Furrer, K., Opitz, I., Weder, W., Rothschild, S.I., Ochsenbein, A., Zippelius, A., Addeo, A., Mark, M., Eboulet, E.I., Hayoz, S., Thierstein, S., Betticher, D.C., Ris, H.-B., Stupp, R., Curioni-Fontecedro, A., Peters, S., Pless, M., Früh, M.
Publikováno v:
In ESMO Open April 2022 7(2)
Autor:
Gao, Y., Weenink, B., van den Bent, M.J., Erdem-Eraslan, L., Kros, J.M., Sillevis Smitt, PAE, Hoang-Xuan, K., Brandes, A.A., Vos, M., Dhermain, F., Enting, R., Ryan, G.F., Chinot, O., Ben Hassel, M., van Linde, M.E., Mason, W.P., Gijtenbeek, J.M.M., Balana, C., von Deimling, A., Gorlia, Th, Stupp, R., Hegi, M.E., Baumert, B.G., French, P.J.
Publikováno v:
In European Journal of Cancer May 2018 94:168-178
Autor:
Fazio, N. *, Biffi, R., Maibach, R., Hayoz, S., Thierstein, S., Brauchli, P., Bernhard, J., Stupp, R., Andreoni, B., Renne, G., Crosta, C., Morant, R., Chiappa, A., Luca, F., Zampino, M.G., Huber, O., Goldhirsch, A., de Braud, F., Roth, A.D., Pace, U., Cenciarelli, S., Pozzi, S., Bertani, E., Mura, S., Lorizzo, K., Di Meglio, G., Ravizza, D., Boselli, S., Matter, M., Richter, M., Monfardini, S., Dittrich, C., Häfner, M., Clemens, M.
Publikováno v:
In Annals of Oncology April 2016 27(4):668-673
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
König, D, Savic Prince, S, Hayoz, S, Zens, P, Berezowska, S, Jochum, W, Stauffer, E, Braunersreuther, V, Trachsel, B, Thierstein, S, Mark, M, Schmid, S, Curioni-Fontecedro, A, Addeo, A, Opitz, I, Guckenberger, M, Früh, M, Betticher, D C, Ris, H-B, Stupp, R, Rothschild, S I, Bubendorf, L, Pless, M
Publikováno v:
ESMO open, vol. 8, no. 4, pp. 101595
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. (In Press). ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. (In Press). ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595
BACKGROUND The inclusion of immune checkpoint inhibitors (ICIs) in the treatment of operable stage III non-small-cell lung cancer is becoming a new standard. Programmed death-ligand 1 (PD-L1) protein expression on tumor cells has emerged as the most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa4d7080bd55100876dc0118b69c9bd
Autor:
Coomans, M., Dirven, L., Aaronson, N., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Taphoorn, M.J.B., EORTC Quality Life Grp, EORTC Brain Tumor Grp
Publikováno v:
Neuro-Oncology
Neuro-Oncology, 2022, 24 (12), pp.2159-2169. ⟨10.1093/neuonc/noac097⟩
Coomans, M B, Dirven, L, Aaronson, N, Baumert, B G, van den Bent, M, Bottomley, A, Brandes, A A, Chinot, O, Coens, C, Gorlia, T, Herrlinger, U, Keime-Guibert, F, Malmström, A, Martinelli, F, Stupp, R, Talacchi, A, Weller, M, Wick, W, Reijneveld, J C & Taphoorn, M J B 2022, ' Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period ', Neuro-Oncology, vol. 24, no. 12, pp. 2159-2169 . https://doi.org/10.1093/neuonc/noac097
Neuro-Oncology, 24(12), 2159-2169. Oxford University Press
Neuro-oncology, 24(12), 2159-2169. Oxford University Press
Neuro-Oncology, 24(12), 2159-2169. OXFORD UNIV PRESS INC
Neuro-Oncology, 2022, 24 (12), pp.2159-2169. ⟨10.1093/neuonc/noac097⟩
Coomans, M B, Dirven, L, Aaronson, N, Baumert, B G, van den Bent, M, Bottomley, A, Brandes, A A, Chinot, O, Coens, C, Gorlia, T, Herrlinger, U, Keime-Guibert, F, Malmström, A, Martinelli, F, Stupp, R, Talacchi, A, Weller, M, Wick, W, Reijneveld, J C & Taphoorn, M J B 2022, ' Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period ', Neuro-Oncology, vol. 24, no. 12, pp. 2159-2169 . https://doi.org/10.1093/neuonc/noac097
Neuro-Oncology, 24(12), 2159-2169. Oxford University Press
Neuro-oncology, 24(12), 2159-2169. Oxford University Press
Neuro-Oncology, 24(12), 2159-2169. OXFORD UNIV PRESS INC
Background Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17e7966aa55c8dc2a27e9f649a68c2b
https://hal.science/hal-03976659
https://hal.science/hal-03976659